http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2853823-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93e8f3f0e161df3d09d4b9a837a21e23 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2015-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d2f80a8ce7b6482c260887960fe4488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba1deade285101e73bfe33e8e8aedbf5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7d843a2edb74335bce42a5407094a38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_816274b97bee8226597524d0a015e7fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fcd48e05318ae1a941f47bb5b3ad206 |
| publicationDate | 2021-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2853823-T3 |
| titleOfInvention | PD-L1 antibodies that bind to canine PD-L1 |
| abstract | An isolated antibody or antigen-binding fragment thereof that binds to canine programmed death ligand 1 (canine PD-L1) with specificity comprising a set of three light chain complementarity determining regions (CDRs): CDR light 1 (CDRL1), CDR light 2 (CDRL2), and CDR light 3 (CDRL3); with three heavy chain CDRs: CDR heavy 1 (CDRH1), CDR heavy 2 (CDRH2), and CDR heavy 3 (CDRH3) selected from the group consisting of: (a) wherein CDRH1 comprises the amino acid sequence of SEQ ID NO: 13; (b) wherein CDRH2 comprises the amino acid sequence of SEQ ID NO: 14; (c) wherein CDRH3 comprises the amino acid sequence of SEQ ID NO: 15; (d) wherein CDRL1 comprises the amino acid sequence of SEQ ID NO: 16; (e) where CDRL2 comprises the amino acid sequence of SEQ ID NO: 17; (f) where CDRL3 comprises the amino acid sequence of SEQ ID NO: 18; and (g) wherein CDRH1 comprises the amino acid sequence of SEQ ID NO: 19; (h) where CDRH2 comprises the amino acid sequence of SEQ ID NO: 20: (i) where CDRH3 comprises the amino acid sequence of SEQ ID NO: 21; (j) wherein CDRL1 comprises the amino acid sequence of SEQ ID NO: 22; (k) wherein CDRL2 comprises the amino acid sequence of SEQ ID NO: 23; (l) wherein CDRL3 comprises the amino acid sequence of SEQ ID NO: 24; and wherein the antibody binds to canine PD-L1 and blocks canine PD-L1 from binding to canine programmed death 1 (PD-1). |
| priorityDate | 2014-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.